Jade Biosciences (JBIO) Cash from Investing Activities (2021 - 2026)

Jade Biosciences (JBIO) has 6 years of Cash from Investing Activities data on file, last reported at -$8.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 165.91% year-over-year to -$8.5 million; the trailing twelve-month figure through Mar 2026 stood at -$268.3 million (down 1132.86% YoY), and the FY2025 full-year result was -$247.0 million, down 540.85% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$8.5 million, up from -$98.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $15.4 million in Q1 2023 and bottomed at -$148.7 million in Q3 2025.
• The 5-year median for Cash from Investing Activities is $4.6 million (2022), against an average of -$14.3 million.
• Peak annual rise in Cash from Investing Activities reached 8394.64% in 2022, while the deepest fall reached 50897.5% in 2022.
• A 5-year view of Cash from Investing Activities shows it stood at $14.5 million in 2022, then sank by 61.01% to $5.6 million in 2023, then soared by 132.45% to $13.1 million in 2024, then tumbled by 847.67% to -$98.2 million in 2025, then surged by 91.37% to -$8.5 million in 2026.
• The last three Cash from Investing Activities figures came in at -$8.5 million (Q1 2026), -$98.2 million (Q4 2025), and -$148.7 million (Q3 2025), per Business Quant data.

Peer Comparison